following an abbreviated submission
fluticasone proprionate and formoterol fumarate metered dose inhaler (flutiform®) is accepted for use in NHS Scotland.
Indication under review: in the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)] is appropriate:
• for patients not adequately controlled on ICS and ‘as required’ inhaled short-acting β2
agonist or
• for patients already adequately controlled on both an ICS and a LABA.
Flutiform® should be used in patients for whom fluticasone and formoterol are appropriate choices of corticosteroid and long-acting beta-agonist, respectively, and for whom a metered dose inhaler is an appropriate delivery device. It has demonstrated clinical non-inferiority to another combination product containing a corticosteroid and long-acting beta2-agonist and may offer cost savings.
Download detailed advice102KB (PDF)
Medicine details
- Medicine name:
- fluticasone/formoterol (Flutiform)
- SMC ID:
- 736/11
- Indication:
- for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)] is appropriate: for patients not adequately controlled on ICS and ‘as required' inhaled short-acting β2 / for patients already adequately controlled on both an ICS and a LABA.
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 October 2012